TRANSITION: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod

Trial Profile

TRANSITION: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TRANSITION
  • Most Recent Events

    • 28 Oct 2017 Results (n=637) assessing safety and efficacy, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 12 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 11 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top